Key result
High-potency P2Y12 inhibitor use continues rising among AMI patients undergoing PCI, driven by prasugrel.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Real-world prescribing practices for P2Y12 inhibitors in AMI patients undergoing PCI are evolving, demonstrating increased adoption of high-potency agents like prasugrel in response to recent clinical trials and guideline updates.
Among patients with AMI undergoing PCI, the use of high-potency agents continues to rise. Prasugrel use increased notably after 2019, following the ISAR-REACT 5 (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome) trial and the European guideline updates. These findings reflect an evolving prescribing landscape of P2Y12 receptor inhibitors in contemporary practice.
Fath et al. (2026) studied this question. High-potency P2Y12 receptor inhibitor use, notably prasugrel after 2019, continues to rise among patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: